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Abstract
Background: Flobufen (F) is an original nonsteroidal anti-inflammatory drug with one center of
chirality. 4-Dihydroflobufen (DHF), compound with two chiral centers, is the main metabolite of F
in microsomes and cytosol in all standard laboratory animals. This work describes the
biotransformation of F enantiomers and DHF stereoisomers in isolated male guinea pig
hepatocytes. Guinea pigs were chosen with respect to similarities in F metabolism as in Man found
earlier. R-F, S-F, (2R;4S)-DHF, (2S;4R)-DHF, (2S;4S)-DHF and (2R;4R)-DHF, structurally very
similar compounds, served as substrates in order to observe their interaction with enzymes.
Stereospecificity of the respective enzymes was studied in vitro, using hepatocytes monolayer.
Chiral HPLC using R,R-ULMO column as chiral stationary phase was used for detection and
quantitation of metabolites.
Results:  (2R;4S)-DHF and (2S;4S)-DHF were the principle stereoisomers detected after
incubation with rac-F, R-F and S-F. The ratio of (2R;4S)-DHF/(2S;4S)-DHF ranged from 1.1 to 2.4
depending on the substrate used. (2R;4S)-DHF was the major stereoisomer found after incubation
with (2S;4S)-DHF and (2R;4R)-DHF. (2S;4S)-DHF was the principle stereoisomer found after
incubation with (2R;4S)-DHF and (2S;4R)-DHF. Besides DHF stereoisomers, other metabolites (M-
17203, UM-1 and UM-2) were also detected after incubation of hepatocytes monolayer with F.
Interestingly, these metabolites were not found in incubation of all F forms and DHF with fresh liver
homogenate.
Conclusions: Different activities and stereospecificities of the respective enzymes were observed
for each substrate in primary culture of hepatocytes. Cell integrity is crucial for formation of
secondary metabolites M-17203, UM-1 and UM-2.
Published: 5 June 2003
BMC Pharmacology 2003, 3:5
Received: 8 February 2003
Accepted: 5 June 2003
This article is available from: http://www.biomedcentral.com/1471-2210/3/5
© 2003 Kral et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media 
for any purpose, provided this notice is preserved along with the article's original URL.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/5
Page 2 of 10
(page number not for citation purposes)
Background
Anti-inflammatory drugs are currently the most widely
used among pharmaceutical drugs. Nonsteroidal anti-
inflammatory drugs (NSAIDs) form a significant part of
this group. Their therapeutic effects are accompanied by a
series of adverse effects [1]. NSAIDs in clinical use (e.g.
ibuprofen, diclofenac, ketoprofen) or compounds for
potential use still undergo investigation of their biotrans-
formation [2,3]. Searching for metabolites and observa-
tion of their further fate in the organism lead to a detailed
description of their metabolic pathways in order to better
understand their desired and adverse effects. One of these
NSAIDs is flobufen, 4-(2',4'-difluorobiphenyl-4-yl)-2-
methyl-4-oxobutanoic acid (F). F is one of the outcomes
of the study of the relationship between arylalkanoic acids
and living organisms towards the end of the 1980's [4,5].
F, together with fenbufen [6], belongs to the group of ary-
loxobutyric acids, which are structurally related to aryl-
propionic acids (e.g.: ibuprofen, flurbiprofen,
ketoprofen) [7]. F mechanisms of action and biological
activities have already been reported [8,9].
Metabolism of F was already tested in different species
[10]. In the in vitro experiments conducted on rats, mice,
guinea pigs, mini-pigs, rabbits and dogs, 4-dihydro-
flobufen, 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-
hydroxybutanoic acid (DHF) was discovered to be the
main metabolite [9,10]. In addition to DHF, another
metabolite, 2-(2',4'-difluorobiphenyl-4-yl)-acetic acid
(M-17203), was found in isolated hepatocytes [9], in
urine and in faeces of rats [9,10]. DHF seems to be trans-
formed to its secondary metabolite M-17203. The biolog-
ical activities of DHF and M-17203 have already been
reported [11,12].
F and DHF are chiral compounds with one and two asym-
metric carbons, respectively. Our first study was focused
on the biotransformation of F in rats [9]. Unfortunately,
preliminary  in vivo experiments in Man (unpublished
data) revealed differences in F metabolites excreted by rat
and Man. The following preliminary in vivo experiments
revealed that the guinea pig is the most convenient and
the nearest species for description of F metabolism in
Man.
Our last study described chiral metabolism of F in guinea
pig [manuscript submitted for publication]. Investigation
of F biotransformation in vitro (microsomes and cytosol)
showed DHF stereoisomers as the only metabolites in
these two subcellular fractions. In vivo experiments
revealed the formation of several other metabolites: M-
17203, UM-1 and UM-2. These results indicate that these
metabolites are formed in some other liver cell compart-
ment, in intact liver cell or in extrahepatic tissue.
This work reports about the investigation of F metabolism
in primary culture of hepatocytes, because it represents a
more comprehensive experimental system for evaluation
of drug metabolism [13]. Fresh liver homogenate and pri-
mary culture of hepatocytes were compared in order to
prove the key role of cell integrity in the formation of M-
17203. Primary culture of hepatocytes was also used in
order to determine stereospecificity of DHF stereoisomer
formation using individual enantiomers of F as substrates
and mutual chiral inversion among DHF stereoisomers.
Results
Primary culture of hepatocytes
Incubation with rac-F
Primary cultures of hepatocytes were incubated with rac-F
in five concentrations (25, 50, 75, 100, 200 µM). All four
DHF stereoisomers and M-17203 were detected. Their
clearances are summarized in Table 1. The production of
all DHF stereoisomers culminated between 2 and 4h of
incubation. The ratio of the most produced stereoisomers,
(2R;4S)-DHF/(2S;4S)-DHF, did not change strongly and
ranged from 1.3 to 1.9. Formation of M-17203 increased
several times from 8 to 24 h of incubation and the shape
of the curve (production of M-17203 vs. time) predicted
growing production after 24 h. In addition to DHF stere-
oisomers and M-17203, two other unknown metabolites,
marked as UM-1 and UM-2, were detected. UM-2 was
detected already after 2 h of incubation while UM-1 was
detected only after 24 h of incubation. UM-1 and UM-2
production is summarized in Table 2.
Incubation with R-F
R-F, in the same concentrations as rac-F, was incubated
with hepatocytes. All four DHF stereoisomers and M-
17203 were detected. The production of all DHF stereoi-
somers culminated again between 2 and 4 h of incuba-
tion. Formation of M-17203 had the same characteristic
increase from 8 to 24 h of incubation as in incubation
with rac-F (see Table 1). M-17203 was produced to a lesser
extent than after incubation with rac-F. (2R;4S)-DHF was
the most produced stereoisomer, as expected. Significant
amounts of (2S;4S)-DHF, which is the direct product of S-
F, were also detected. The ratio of (2R;4S)-DHF/(2S;4S)-
DHF ranged from 1.5 to 4.1. UM-1 and UM-2 were
formed in lesser amounts than after incubation with rac-
F. Results are summarized in Table 3.
Incubation with S-F
S-F, in the same range of concentrations as rac-F and R-F,
was incubated with hepatocytes. All four DHF stereoi-
somers and M-17203 were detected. The maximum of
DHF stereoisomer formation was between 2–4 h, and
retarded formation of M-17203 displayed the same ten-
dency as for incubation with rac-F and R-F (see Table 1).
M-17203 was produced to a greater extent than afterBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/5
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incubation with rac-F or R-F. Interestingly (2R;4S)-DHF
remained the most produced stereoisomer. (2S;4S)-DHF
was produced in smaller yields than after incubation with
rac-F and R-F, within 8 h of incubation. Its concentration
after 24 h of incubation remained at the same level as after
8 h of incubation, while the concentrations of other DHF
stereoisomers decreased. The ratio of (2R;4S)-DHF/
(2S;4S)-DHF ranged from 1.0 to 1.5. The formation of
UM-1 and UM-2 in time was the same as after incubation
with rac-F and R-F, but their concentrations were higher
compared to the previous incubations. Results of their
production are summarized in Table 4.
Incubation with (2R;4S)-DHF
Primary cultures of hepatocytes were incubated with
(2R;4S)-DHF in concentrations 50 and 100 µM. The max-
imum of DHF stereoisomer formation was between 2 h
and 4 h of incubation. Mild growth of M-17203 appeared
within 8 h of incubation and it increased several times
between 8 h and 24 h of incubation. Results are summa-
rized in Table 5. Chiral inversion at carbon 2 and signifi-
cant production of (2S;4S)-DHF were found in
hepatocytes after incubation with (2R;4S)-DHF. While its
concentration decreased between 4 h and 8 h, it started to
grow again from 8 h until 24 h. UM-1 was detected only
after 24 h incubation while UM-2 was detected again after
2 h of incubation. Growing production of UM-2 was
observed within the whole 24 h incubation period (Table
6). UM-2 was found as the principle metabolite after 24 h
incubation.
Incubation with (2S;4R)-DHF
Primary cultures of hepatocytes were incubated with
(2S;4R)-DHF in concentrations 50 and 100 µM. The char-
acteristics of formed DHF stereoisomers and time course
of M-17203 formation were very similar to results
obtained from the previous incubation with (2R;4S)-
DHF, and they are summarized in Table 5. Significant pro-
duction of (2S;4S)-DHF and (2R;4S)-DHF revealed chiral
inversion at both carbons 2 and 4. UM-1 was only
detected after 24h of incubation (Table 6). UM-2
remained the principle metabolite and it was even pro-
duced to a larger extent than after incubation with
(2R;4S)-DHF.
Incubation with (2S;4S)-DHF
Primary cultures of hepatocytes were incubated with
(2S;4S)-DHF in concentrations 50 and 100 µM. Concen-
tration and time characteristics of DHF stereoisomers and
M-17203 formation were very similar to the results
obtained from the previous incubations with DHF stereoi-
somers. They are summarized in Table 5. A significant
amount of (2R;4S)-DHF was produced, due to chiral
inversion at carbon 2. This inversion at carbon 2 (S to R)
proceeded to a higher extent within 24 h compared to
reverse inversion (R to S) after incubation with (2R;4S)-
DHF. UM-1 was only detected after 24 h incubation
Table 1: Biotransformation of rac-F, R-F and S-F in isolated guinea pig hepatocytes.
Substrate Incubation time [h] Apparent actual clearance [h-1 × 10-3]
M-17203 (2R;4S)-DHF (2S;4R)-DHF (2S;4S)-DHF (2R;4R)-DHF
2 1.8 ± 0.7 111.2 ± 8.6 10.8 ± 0.1 57.5 ± 5.0 2.3 ± 0.0
4 1.4 ± 0.2 67.7 ± 0.5 7.1 ± 0.4 42.4 ± 0.6 0.8 ± 0.1
rac-F
8 1.6 ± 0.1 22.8 ± 1.3 1.6 ± 0.2 12.8 ± 1.0 0.1 ± 0.0
24 3.8 ± 0.8 4.2 ± 0.2 0.3 ± 0.0 3.6 ± 0.1 -
2 1.6 ± 0.5 147.1 ± 11.8 1.6 ± 0.4 38.0 ± 3.8 6.3 ± 0.5
4 1.2 ± 0.1 91.1 ± 2.7 3.4 ± 0.1 33.6 ± 1.4 2.0 ± 0.1
R-F
8 1.4 ± 0.1 32.3 ± 0.8 1.0 ± 0.8 12.9 ± 0.1 0.2 ± 0.0
24 2.9 ± 0.0 7.6 ± 1.4 0.2 ± 0.0 4.5 ± 0.5 -
2 2.9 ± 0.2 58.1 ± 3.2 13.3 ± 0.7 56.9 ± 2.6 -
4 2.4 ± 0.3 47.3 ± 1.5 10.2 ± 1.0 44.6 ± 2.1 0.5 ± 0.3
S-F
8 2.0 ± 0.1 20.0 ± 0.4 3.7 ± 0.1 15.8 ± 0.2 0.1 ± 0.0
24 3.0 ± 0.2 4.3 ± 0.5 0.6 ± 0.0 4.9 ± 0.4 0.4 ± 0.1
Apparent actual clearance (Claa) of F metabolites in the isolated hepatocytes after incubation with 100 µM rac-F, R-F and S-F as substrates. Claa is 
expressed as the ratio of actual velocity (mol/l/h) and substrate concentration (mol/l), (mean value ± S.D., n = 4).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/5
Page 4 of 10
(page number not for citation purposes)
(Table 6). UM-2 remained the principle metabolite and it
was even produced to a larger extent than after the incuba-
tions with (2R;4S)-DHF and (2S;4R)-DHF.
Incubation with (2R;4R)-DHF
Primary cultures of hepatocytes were incubated with
(2R;4R)-DHF in concentrations 50 and 100 µM. Clear-
ances of DHF stereoisomers and M-17203 production
were very similar to all three previous cases. Results are
summarized in Table 5. Intensive chiral inversion at car-
bon 4 led to significant production of (2R;4S)-DHF. Chi-
ral inversion at this carbon seems to be almost
unidirectional. UM-1 was detected only after 24 h of incu-
bation (Table 6). UM-2 remained the major metabolite
even when its production was the lowest compared to all
three previous incubations with DHF stereoisomers.
Liver homogenate
Fresh liver homogenate from guinea pig was incubated
with rac-F (0.5 and 1.0 mM) and with rac-DHF (0.12 and
0.24 mM). Individual DHF stereoisomers and F were
detected and quantified. The results are summarized in
Table 7. DHF stereoisomers and F were the only structures
detected after incubations with rac-F or rac-DHF. No
amounts of M-17203, UM-1 and UM-2 were detected
either in incubations with rac-F or rac-DHF.
Discussion
Investigation of F metabolism in isolated guinea pig hepa-
tocytes and in fresh liver homogenate, improved our
knowledge of its fate in this species, which is related to F
metabolism in Man. Description of the formation of prin-
ciple metabolites could be useful for determination of the
stereospecifities of the respective enzymes. Knowledge
Table 2: UM-1 and UM-2 production after incubation with rac-F.
peak area (AU × s × 104)
incubation time (h)
24 8 2 4
25 µM
UM-1 - - - 5.1 ± 0.1
UM-2 23.6 ± 1.1 46.8 ± 2.4 66.8 ± 1.2 120.0 ± 1.2
50 µM
UM-1 - - - 17.3 ± 1.1
UM-2 27.9 ± 0.4 67.3 ± 2.6 127.1 ± 6.7 185.2 ± 4.1
75 µM
UM-1 - - - 24.8 ± 4.0
UM-2 29.8 ± 1.7 79.3 ± 3.4 164.1 ± 10.2 250.0 ± 27.0
100 µM
UM-1 - - - 41.9 ± 10.3
UM-2 30.9 ± 3.6 91.8 ± 2.7 206.8 ± 13.2 331.5 ± 26.2
200 µM
UM-1 - - - 42.6 ± 2.3
UM-2 23.4 ± 2.0 102.9 ± 6.1 277.2 ± 12.1 521.3 ± 34.1
UM-1 and UM-2 production in isolated guinea pigs hepatocytes after 
incubation with rac-F (mean value ± S.D., n = 4).
Table 3: UM-1 and UM-2 production after incubation with R-F.
peak area (AU × s × 104)
incubation time (h)
24 8 2 4
25 µM
UM-1 - - - 10.0 ± 0.6
UM-2 18.4 ± 2.1 39.5 ± 2.7 55.2 ± 3.3 111.4 ± 14.3
50 µM
UM-1 - - - 17.4 ± 2.3
UM-2 23.8 ± 1.9 56.3 ± 2.7 100.7 ± 2.2 172.9 ± 0.6
75 µM
UM-1 - - - 24.2 ± 3.3
UM-2 22.0 ± 0.5 57.6 ± 4.2 129.5 ± 1.6 234.1 ± 5.0
100 µM
UM-1 - - - 36.2 ± 5.6
UM-2 19.3 ± 1.3 61.7 ± 3.1 144.8 ± 7.9 263.7 ± 2.5
200 µM
UM-1 - - - 47.6 ± 4.6
UM-2 16.1 ± 2.1 60.4 ± 2.9 178.3 ± 9.2 398.2 ± 17.2
UM-1 and UM-2 production in isolated guinea pigs hepatocytes after 
incubation with R-F (mean value ± S.D., n = 4).
Table 4: UM-1 and UM-2 production after incubation with S-F.
peak area (AU × s × 104)
incubation time (h)
24 8 2 4
25 µM
UM-1 - - - 11.8 ± 0.6
UM-2 20.5 ± 1.3 48.8 ± 4.3 58.2 ± 3.8 135.6 ± 7.8
50 µM
UM-1 - - - 23.8 ± 1.5
UM-2 30.5 ± 2.5 68.7 ± 4.4 119.7 ± 9.3 209.5 ± 10.3
75 µM
UM-1 - - - 22.7 ± 3.6
UM-2 33.8 ± 1.6 78.1 ± 4.0 156.3 ± 6.3 270.3 ± 0.5
100 µM
UM-1 - - - 20.3 ± 12.6
UM-2 35.1 ± 4.5 89.6 ± 0.7 188.1 ± 3.5 333.8 ± 7.8
200 µM
UM-1 - - - 54.3 ± 0.5
UM-2 45.2 ± 6.6 116.2 ± 0.1 298.8 ± 0.5 549.6 ± 22.5
UM-1 and UM-2 production in isolated guinea pigs hepatocytes after 
incubation with S-F (mean value ± S.D., n = 4).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/5
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from these experiments could also contribute to better
understanding of the relationship between mutual inver-
sions among individual DHF stereoisomers.
Metabolism of F in isolated hepatocytes
The concentration range of substrates with respect to their
solubility and toxicity was the limiting factor for designed
experiments. The dependence of metabolite production
on proposed substrate concentrations did not show satu-
ration characteristics, therefore, no kinetic constants; such
as apparent Michaelis constant, apparent maximal veloc-
ity and apparent intrinsic clearance could be calculated.
Metabolism of F in primary cultures of guinea pig
hepatocytes differed qualitatively from that in micro-
somes and cytosol. In addition to DHF stereoisomers,
three other metabolites, M-17203, UM-1 and UM-2, were
found (Table 2,3,4). Exact chemical structure of UM-1 and
UM-2 has not been defined yet, but their UV-spectral
properties confirm their relation to structures close to M-
17203 and DHF (thanks to delocalisation of π electrons
on C4 in the side chain of the structure) (Fig. 1). It is
thought that this metabolite could be a product of second
phase biotransformation (a conjugate) or a compound
like M-17203 and DHF but with the side carbon chain
substituted in another way. Metabolism of the structurally
related compound ibuprofen adverts to hydroxylation of
the side chain [2,14]. The structure could also be derived
from fenbufen metabolites found in Man [6] because fen-
bufen is structurally the most related compound to F.
Our previous work with isolated microsomes and cytosol
showed that (2R;4S)-DHF and (2R;4R)-DHF originated
strictly from R-F and (2S;4R)-DHF with (2S;4S)-DHF orig-
inated only from S-F [manuscript submitted for
publication].
This rule was also confirmed in this work, in the incuba-
tion with rac-F. (2R;4S)-DHF and (2S;4S)-DHF were
determined as the main DHF stereoisomers originating
from R-F and S-F, respectively. The amounts of the other
two stereoisomers were negligible. This shows that reduc-
ing enzymes form stereospecificaly DHF stereoisomers
with S configuration at carbon 4. All four DHF stereoi-
somers had the same characteristics: their production cul-
minated between 2 h and 4 h and afterwards their
concentrations decreased probably due to their following
biotransformation.
Table 5: Biotransformation of individual DHF stereoisomers in isolated guinea pig hepatocytes
Substrate Incubation time [h] Apparent actual clearance [h-1 × 10-3]
M-17203 (2R;4S)-DHF (2S;4R)-DHF (2S;4S)-DHF (2R;4R)-DHF
2 1.0 ± 0.2 218.2 ± 0.5 2.6 ± 0.0 21.3 ± 0.6 1.5 ± 0.4
4 1.2 ± 0.1 93.7 ± 1.2 1.6 ± 0.1 19.5 ± 0.5 2.3 ± 0.1
(2R;4S)-DHF
8 1.1 ± 0.1 24.2 ± 2.0 0.8 ± 0.0 6.7 ± 0.0 0.2 ± 0.0
24 3.1 ± 0.1 6.9 ± 1.4 0.2 ± 0.0 3.0 ± 0.4 0.1 ± 0.0
2 1.7 ± 0.0 16.7 ± 0.4 115.6 ± 1.8 36.8 ± 1.3 1.8 ± 0.3
4 1.9 ± 0.1 20.1 ± 0.4 47.1 ± 1.1 34.7 ± 0.4 1.4 ± 0.3
(2S;4R)-DHF
8 1.7 ± 0.0 9.6 ± 0.1 7.7 ± 0.5 14.3 ± 0.1 0.1 ± 0.0
24 3.2 ± 0.2 2.1 ± 0.6 1.2 ± 0.5 6.0 ± 0.5 —
2 2.1 ± 0.2 35.1 ± 1.7 5.2 ± 0.4 179.2 ± 6.0 —
4 2.1 ± 0.0 26.2 ± 0.3 4.3 ± 0.0 54.8 ± 1.2 0.2 ± 0.0
(2S;4S)-DHF
8 1.3 ± 0.1 9.0 ± 0.5 2.1 ± 0.3 12.7 ± 0.8 —
24 3.8 ± 0.1 2.2 ± 0.5 0.1 ± 0.0 5.0 ± 0.6 —
2 — 122.4 ± 3.5 19.6 ± 0.5 12.3 ± 0.3 84.6 ± 6.4
4 0.8 ± 0.0 71.6 ± 1.6 11.7 ± 0.4 15.1 ± 0.1 8.0 ± 0.7
(2R;4R)-DHF
8 1.4 ± 0.1 21.5 ± 1.3 2.2 ± 0.1 8.2 ± 0.3 0.4 ± 0.0
24 3.3 ± 0.3 3.8 ± 0.3 0.3 ± 0.0 2.7 ± 0.1 —
Apparent actual clearance (Claa) of DHF metabolites in the isolated hepatocytes after incubation with 100 µM individual DHF isomers as sub-
strates. Claa is expressed as the ratio of actual velocity (mol/l/h) and substrate concentration (mol/l), (mean value ± S.D., n = 4).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/5
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Incubations with individual enantiomers of F should con-
firm the stereospecific formation of the respective DHF
stereoisomers. Increment of (2R;4S)-DHF formation
occurred as expected but also a considerable amount of
(2S;4S)-DHF was formed. Due to this result, one assump-
tion arose: inversion of R-F to S-F or inversion of (2R;4S)-
DHF to (2S;4S)-DHF, or both cases together, could
increase the final amount of (2S;4S)-DHF. The inversion
of R-F to S-F has been already described in rats [15] and in
ruminants [16]. This type of unidirectional inversion of R
enantiomers of arylpropionic acids to Senantiomers has
been reported many times [17–24]. The main enzyme
responsible for this chiral inversion, 2-arylpropionyl-CoA
epimerase, was even isolated and characterized in rats
[25]. Long chain acyl-CoA synthetase seems to be the key
enzyme at the beginning of the inversion process and it
catalyses the formation of 2-arylpropionyl-CoA [26].
More interesting results were obtained in incubation with
S-F. (2R;4S)-DHF remained the most produced DHF ster-
eoisomer within 8 h of incubation. Inversion of S-F to R-
F or inversion of (2S;4S)-DHF to (2R;4S)-DHF or combi-
nation of both of them must be taken into account. Inver-
sion of S-F to R-F has already been suspected in rats [15].
Bi-directional inversions of ibuprofen and ketoprofen
have already been described in both guinea pigs [27] and
mice [28].
Inversions among DHF stereoisomers and substrate pref-
erence in the production of M-17203, UM-1 and UM-2
became clearer using individual DHF stereoisomers as
substrates (Table 5, 6).
Incubation of isolated hepatocytes with (2R;4S)-DHF
showed that it is inverted predominantly to (2S;4S)-DHF.
This could easily explain the strong increase of (2S;4S)-
DHF concentration after incubation with R-F.
Incubation with (2S;4R)-DHF showed that the main DHF
stereoisomer, (2S;4S)-DHF, is produced almost two times
more than the second one, (2R;4S)-DHF. The formed
(2S;4S)-DHF probably served as substrate for the follow-
ing enzymatic transformation to (2R;4S)-DHF, but fast
inversion at carbon 4 (S to R) and slower inversion at car-
bon 2 (Sto R) explains why (2S;4S)-DHF is the most pro-
duced DHF stereoisomer during 24 h incubation.
Incubation with (2S;4S)-DHF proved that it is mainly
inverted to (2R;4S)-DHF. With respect to the ways of
inversion mentioned above, the equilibrium between
(2R;4S)-DHF and (2S;4S)-DHF arises. This equilibrium is
moved in the direction of (2R;4S)-DHF formation. Con-
sidering these facts, it can be explained why (2R;4S)-DHF
is the principle DHF stereoisomer produced during incu-
bation with S-F.
Incubation with (2R;4R)-DHF showed that it is trans-
formed predominantly to (2R;4S)-DHF. Therefore, it can
be reasonably explained, why negligible concentration of
(2R;4S)-DHF was found after incubation of rac-F, R-F, S-F,
(2R;4S)-DHF, (2S;4R)-DHF and (2S;4R)-DHF. (2R;4R)-
DHF is easily transformed to (2R;4S)-DHF. The concen-
tration of (2R;4S)-DHF was 6 times higher after incuba-
tion with (2R;4R)-DHF than other DHF stereoisomers at
the maximum of their production.
Taking all these results into account, we can conclude that
DHF stereoisomers are stereoselectively utilized by the
respective enzymes. Investigation of chiral inversion
among individual DHF stereoisomers showed that
(2R;4R)-DHF is the most convenient substrate for the
enzymes.
M-17203 was selectively formed from S-F. M-17203 was
produced two times higher than from R-F (Table 1).
Incubations with individual DHF stereoisomers confirm
Table 6: UM-1 and UM-2 production after incubation with 
individual DHF stereoisomers.
peak area (AU × s × 104)
incubation time (h)
24 8 2 4
substrate (2R;4S)-DHF 50 µM
UM-1 - - - 18.0 ± 0.5
UM-2 8.7 ± 0.6 41.4 ± 3.7 72.1 ± 4.0 167.7 ± 8.0
substrate (2R;4S)-DHF 100 µM
UM-1 - - - 32.3 ± 0.2
UM-2 10.4 ± 0.1 48.2 ± 1.5 102.7 ± 6.1 228.6 ± 4.2
substrate (2S;4R)-DHF 50 µM
UM-1 - - - 31.1 ± 4.2
UM-2 10.0 ± 1.1 48.9 ± 5.0 95.4 ± 3.5 196.1 ± 11.7
substrate (2S;4R)-DHF 100 µM
UM-1 - - - 37.7 ± 3.3
UM-2 69.0 ± 0.5 43.0 ± 1.1 133.1 ± 7.3 237.5 ± 5.8
substrate (2S;4S)-DHF 50 µM
UM-1 - - - 18.9 ± 2.8
UM-2 71.7 ± 2.4 140.7 ± 5.5 171.3 ± 2.2 248.6 ± 15.8
substrate (2S;4S)-DHF 100 µM
UM-1 - - - 39.3 ± 2.2
UM-2 119.1 ± 7.5 228.1 ± 7.8 299.7 ± 18.7 401.5 ± 9.1
substrate (2R;4R)-DHF 50 µM
UM-1 - - - 21.9 ± 1.8
UM-2 11.2 ± 0.1 17.9 ± 0.1 69.7 ± 3.7 143.6 ± 8.3
substrate (2R;4R)-DHF 100 µM
UM-1 - - - 33.9 ± 3.3
UM-2 11.3 ± 8.1 28.3 ± 1.0 99.9 ± 4.4 193.4 ± 7.2
UM-1 and UM-2 production in isolated guinea pigs hepatocytes after 
incubation with individual DHF stereoisomers (mean value ± S.D., n 
= 4).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/5
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the substrate dependence production of M-17203. We
observed that DHF stereoisomers formed from S-F were
stereoselectively chosen for M-17203 formation. (2S;4S)-
DHF led to formation of M-17203 to the largest extent.
Incubations with the other 3 DHF stereoisomers showed
significantly lower production of M-17203 (Table 5).
Formation of UM-1 and UM-2 can be explained by a sim-
ilar way. Productions of UM-1 and UM-2 were signifi-
cantly higher after incubations with rac-F and S-F
compared to R-F (Table 2,3,4). The stereoselectivity was
also observed after incubation with individual DHF stere-
oisomers (Table 6). UM-1 and UM-2 were predominantly
formed from (2S;4S)-DHF and (2S;4R)-DHF, which are
stereoisomers originated from S-F. All enzymes producing
UM-1, UM-2 and M-17203 prefered S-F as substrate.
Liver homogenate
Our previous work revealed formation in vivo of M-17203
from F in guinea pigs (in urine and in faeces), but also its
absence in F incubations with subcellular fractions
(microsomes and cytosol) [manuscript submitted for
publication]. Results from hepatocytes showed that M-
17203 arose in intact liver cells. Incubations of fresh liver
homogenate with rac-F and with rac-DHF did not lead to
any production of M-17203 (Table 7). In addition, no
amount of UM-1 and UM-2 was detected. With respect to
these results, we can conclude that the integrity of the
hepatocytes is essential for the formation of M-17203,
UM-1 and UM-2. Integrity of the cell as a critical point has
already been proven in other enzymatic reactions, like
chiral inversions of profens [21].
The achieved results from our investigations allow us to
suggest a scheme for F biotransformation in hepatocyte
primary culture of male guinea pigs (Fig. 1).
Conclusions
This study described metabolic pathways of rac-F and its
enantiomers and DHF-stereoisomers in isolated guinea
pig hepatocytes. Different activities of the respective
enzymes were observed for each substrate. Incubation
with liver homogenate showed that hepatocyte integrity is
essential for M-17203, UM-1 and UM-2 formation. Both
chiral inversions of DHF stereoisomers and cell integrity,
which are responsible for the formation of the three addi-




Rac-F, R-F and S-F, (2R;4S), (2S;4R), (2S;4S), (2R;4R)-
DHF and M-17203 were obtained from Biotest (Prague,
Czech Republic). Coenzymes (NADP+, NADPH, NADH)
and enzyme glucose-6-posphate dehydrogenase (Glc-6P-
DH) were provided by Boehringer-Mannheim (Ger-
many). Magnesium chloride (MgCl2), trifluoroacetic acid
(TFAA), insulin, powdered Williams E medium, pow-
dered HAM 12 medium, fetal bovine serum, streptomy-
cin, penicillin, rat tail collagen, collagenase, Trypan blue
and glucose-6-posphate (Glc6P) were purchased from
Table 7: Biotransformation of rac-F and rac-DHF in fresh liver homogenate.
incubation time (h) activity nmol/mg protein
M-17203 (2R;4S)-DHF (2S;4R)-DHF (2S;4S)-DHF (2R;4R)-DHF F
substrate rac-F 0.5mM
1 - 11.1 ± 0.1 1.6 ± 0.1 3.9 ± 0.1 9.1 ± 0.2 89.2 ± 1.2
2 - 14.8 ± 0.1 3.2 ± 0.1 7.0 ± 0.1 16.0 ± 0.4 81.2 ± 1.2
4 - 18.3 ± 1.0 5.1 ± 0.3 7.7 ± 0.0 18.1 ± 0.4 69.5 ± 2.3
substrate rac-F 1.0 mM
1 - 14.2 ± 0.6 1.2 ± 0.0 4.5 ± 0.3 6.8 ± 0.3 138.4 ± 27.6
2 - 22.3 ± 0.6 2.9 ± 0.1 9.4 ± 0.3 15.1 ± 0.4 108.4 ± 5.8
4 - 30.7 ± 0.8 6.0 ± 0.2 10.5 ± 0.4 20.3 ± 0.5 106.4 ± 4.1
substrate rac-DHF 0.12 mM
1 - 5.4 ± 0.1 5.1 ± 0.1 5.7 ± 0.1 4.9 ± 0.1 0.3 ± 0.0
2 - 5.3 ± 0.2 5.5 ± 0.2 5.9 ± 0.3 5.1 ± 0.4 0.5 ± 0.1
4 - 5.4 ± 0.0 5.4 ± 0.0 4.7 ± 0.1 4.0 ± 0.0 1.1 ± 0.0
substrate rac-DHF 0.24 mM
1 - 12.2 ± 0.3 11.7 ± 0.3 12.5 ± 0.3 11.5 ± 0.3 0.6 ± 0.0
2 - 11.9 ± 0.2 11.9 ± 0.2 12.8 ± 0.2 11.8 ± 0.2 0.7 ± 0.1
4 - 12.1 ± 0.5 11.9 ± 0.5 11.4 ± 0.5 10.4 ± 0.5 2.0 ± 0.1
Activity of the respective enzymes in guinea pigs fresh liver homogenate after incubation with rac-F and rac-DHF (mean value ± S.D., n = 4).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/5
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Sigma (Prague, Czech Republic). Dimethylsulfoxid
(DMSO) and bovine serum albumin (BSA) were bought
from Fluka (Prague, Czech Republic). Methanol (MeOH),
2-propanol (IPA) and n-hexane (all solvents HPLC grade)
were from Merck (Prague, Czech Republic). Water from
the Milli-Q-RG Ultra-Pure Water System from Millipore
(Prague, Czech Republic) was used in all cases.
Animals
Male guinea pigs (Cavia aperea f. var. TRIC, 15–16 weeks,
weight 650–700 g) were obtained from Biotest (Konarov-
ice, Czech Republic). They were kept under standard con-
ditions with free access to food and water. Experiments
with animals were carried out according to Guide for the
care and use of laboratory animals (Protection of Animals
against Cruelty Act. No. 246/92 Coll., Czech Republic).
The animals were killed by decapitation in total inhala-
tion anesthesia. The liver tissue was removed from abdo-
men after bleeding out and underwent procedure of
isolation of hepatocytes.
Preparation of liver homogenate
Liver tissue from 4 guinea pigs was homogenized with
phosphate buffer pH 7.4 (PBS) in the ratio 1/6 (w/v) in
Potter and Elvehjem homogenizer. This fresh homoge-
nate was used for incubations.
Isolation of hepatocytes
Hepatocytes were obtained by a two-step collagenase
method [29]. In the first step, the whole liver (10–15 g)
was washed with 100 ml of solution without calcium,
with aim of removing the rest of blood and making the
cell-cell junction weaker. In the second step, hepatocytes
were released by action of collagenase (50 mg/100 ml) in
perfusion solution. Second perfusion lasted 6–8 min (re-
circulation system). Isolated hepatocytes were rewashed
three times and mixed together with culture medium. The
culture medium consisted of a 1:1 mixture of Ham F12
and Williams' E, supplemented as described [13,30]. The
viabilities of cells measured by Trypan blue staining
according to Sigma protocol were 75–90%. Three million
of viable cells in 3 ml of culture medium were placed into
60 mm plastic dishes pre-coated with collagen. The foetal
calf serum was added in culture medium (5%) to favour
the cells attachment during the first four hours after plat-
ing. Then the medium was exchanged with a fresh one
without serum. The cultures were maintained at 37°C in
ahumid atmosphere of air and 5% CO2.
Incubations
Liver homogenate: The substrates (rac-F, R-F and S F), dis-
solved in 10% of MeOH and 90% of PBS, were prepared
in the concentrations 0.5 and 1.0 mM. Stock solutions of
rac-DHF had to be made in another way because of its low
solubility in water solution. Total weight of solid rac-DHF
was first dissolved in 50% DMSO in water, then 0.1 and
0.2 ml of this solution were mixed with 0.9 and 0.8 ml of
PBS, respectively. Final concentration of rac-DHF in incu-
bation mixture was 0.12 and 0.24 mM. Stock solutions of
coenzymes (NADH, NADPH) were prepared in concen-
tration 6 mM (in redistilled water). NADPH regenerating
system (NADPH-RS) was prepared in final concentration
6 mM NADP+, 45 mM Glc6P, 8 U/ml Glc6P-DH, 49.4 mM
MgCl2 in 0.1 M PBS. Incubations were performed at 37°C
for 1, 2 and 4 h. Final volume of reaction mixture was 3
ml (1.0 ml of substrate, 1.0 ml of coenzyme, 1.0 ml of
liver homogenate). Incubation was stopped with cooling
to 0°C and with addition of 1 ml 5 M H3PO4. Acidified
incubation mixtures were extracted three times with dis-
tilled ethylacetate (EA). Extracts were evaporated and the
dry samples were used for HPLC assessment.
Hepatocytes monolayers (18–24 h after isolation) were incu-
bated with rac-F or individual R-F or S-F (25–200 µM) and
also with individual DHF stereoisomers (50 and 100 µM)
as substrates. Aliquots of medium (0.5 ml) were collected
in the intervals of 0, 2, 4, 8 and 24 h. All samples of
medium were acidified with 0.1 ml of 5 M phosphoric
acid and extracted with distilled EA. The extracts were
evaporated to dryness under vacuum. The dry samples
were redissolved in 400 µl of mobile phase prior to their
HPLC injection.
Analytical assessment
HPLC method was used for detection and quantification
of all metabolites and substrates. Under the following
conditions, separation of DHF stereoisomers from each
other, M-17203 and F was achieved in one chromato-
graphic run: chiral stationary phase (silica modified with
3,5-dinitrobenzoyl diphenylethylendiamine, where π-π
Figure 1
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interactions are essential in the separation process), work-
ing in normal phase mode, was used; all analytical deter-
minations were performed with the R,R-ULMO column
(250 × 0.46 cm I.D.) from Regis Technologies (Morton
Grove, Illinois, USA); mobile phase consisted of n-
hexan:IPA:TFAA (98.5:1.5:0.1 v/v/v); flow rate 1.0 ml/
min and a temperature of 25°C in the column compart-
ment were set up; 240 nm was the optimal wavelength for
DHF and M-17203 determination whereas 275 nm was
the optimal wavelength for F determination.
100 µl of samples reconstituted in mobile phase for DHF
separation (total volume 400 µl) was injected into the col-
umn. Each sample, made in triplicate, was measured indi-
vidually. The final result represents the mean of these
three individual measurements. Reproducibility of
metabolites and substrate determination was tested dur-
ing HPLC method development. The S.D. of consequent
assessments was ≤ 2%. Student t-test was used for statisti-
cal evaluation of results. Extraction recovery of F enanti-
omers and DHF stereoisomers in pure medium was 85%
(S.D. 2%). The calibration curves were prepared in the
range 40 nM-50 µM for M-17203, 35 nM-50 µM for DHF
stereoisomers and in the range 40 nM-100 µM for F. The
measures of linearity (r2) were 0.9998 for (2R;4S)-DHF,
0.9994 for (2S;4R)-DHF, 0.9989 for (2S;4S)-DHF, 0.9997
for (2R;4R)-DHF, 0.9996 for F and 0.9998 for M-17203.
The limit of quantification (LOQ) for F enantiomers was
40 nM, for DHF stereoisomers 35 nM and for M-17203 40
nM. Optical purity was > 99% for individual F enantiom-
ers, 99.1% for (2R;4S)-DHF, 100.0% for (2S;4R)-DHF,
96.1% for (2S;4S)-DHF and 97.0% for (2R;4R)-DHF. The
successful separation process was characterized by the res-
olution (RS) of individual compounds as follows: M-
17203/(2R;4S)-DHF (5.0) (2R;4S)-DHF/(2S;4R)-DHF
(1.7), (2S;4R)-DHF/(2S;4S)-DHF (4.8), (2S;4S)-DHF/
(2R;4R)-DHF (1.8) and (2R;4R)-DHF/F (2.1).
Chromatographic instrumentation consisted of low-pres-
sure gradient pump, degasser of mobile phase,
autosampler, column thermostat and photodiode array
detector. All components were products of Shimadzu
(Prague, Czech Republic). Data acquisition and evalua-
tion were performed using the Chromatography Labora-
tory Automated Software System Class VP (version 6.12)
from Shimadzu (Prague, Czech Republic). Illustrative
chromatogram resulting from these chromatographic
conditions is shown in Fig. 2.
Apparent actual clearance for each metabolite was calcu-
lated as actual velocity divided by initial substrate
concentration:   (Claa – apparent actual clear-
ance, Va – actual velocity [mol/l/h], [Si] – initial concen-
tration of substrate).
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